• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aerpio Pharmaceuticals, Inc.

    5/26/21 5:01:02 PM ET
    $ARPO
    Major Pharmaceuticals
    Health Care
    Get the next $ARPO alert in real time by email
    SC 13G 1 a052021a.htm SCHEDULE 13G
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
    (Name of Issuer)
    Aerpio Pharmaceuticals, Inc.
    (Title of Class of Securities)
    Common Stock, $0.0001 Par Value Per Share

    (CUSIP Number)

    00810B105
    (Date of Event Which Requires Filing of this Statement)
    May 17, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 00810B105
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,825,000 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,825,000 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,825,000 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 3.9% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     


    CUSIP No. 00810B105
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,825,000 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power   1,825,000 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,825,000 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 3.9% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 00810B105
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,825,000 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,825,000 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,825,000 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 3.9% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:
    Aerpio Pharmaceuticals, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    9987 Carver Road, Cincinnati, OH 45242
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, $0.0001 par value per share
    (“Shares”), of the Issuer held by certain investment funds it manages; (ii)
    Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect
    to Shares held by certain investment funds managed by Point72 Asset
    Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management and Point72 Capital Advisors
    Inc.

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have
    entered into a Joint Filing Agreement, a copy of which is filed with this
    Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this
    Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the
    Act.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:

    Common Stock, $0.0001 Par Value Per Share

    2(e) CUSIP Number:

    00810B105

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on May 25, 2021:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 1,825,000
    (b) Percent of class: 3.9% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,825,000 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,825,000

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 1,825,000
    (b) Percent of class: 3.9% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,825,000 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,825,000

    3. Steven A. Cohen
    (a) Amount beneficially owned: 1,825,000
    (b) Percent of class: 3.9% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,825,000 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,825,000

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own
    directly no Shares. Pursuant to an investment management agreement, Point72
    Asset Management maintains investment and voting power with respect to the
    securities held by certain investment funds it manages. Point72 Capital
    Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen
    controls each of Point72 Asset Management and Point72 Capital Advisors Inc.
    By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934,
    as amended, each of Point72 Asset Management, Point72 Capital Advisors
    Inc. and Mr. Cohen may be deemed to beneficially own 1,825,000 Shares
    (constituting approximately 3.9% of the Shares outstanding). Each of Point72
    Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen disclaims
    beneficial ownership of any of the securities covered by this statement.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable
    Item 8. Identification and Classification of Members of the Group


    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect, other than activities
    solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: May 26, 2021

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    Get the next $ARPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARPO

    DatePrice TargetRatingAnalyst
    7/8/2021$22.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aerpio Pharmaceuticals upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Aerpio Pharmaceuticals from Neutral to Buy and set a new price target of $22.00

      7/8/21 6:10:14 AM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • HC Wainwright resumed coverage on Aerpio Pharmaceuticals

      HC Wainwright resumed coverage of Aerpio Pharmaceuticals with a rating of Hold

      3/15/21 7:37:51 AM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Aerpio Pharmaceuticals, Inc.

      SC 13D - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/8/21 5:30:33 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Aerpio Pharmaceuticals, Inc.

      SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/7/21 5:26:49 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D filed by Aerpio Pharmaceuticals, Inc.

      SC 13D - Aadi Bioscience, Inc. (0001422142) (Subject)

      9/7/21 5:25:38 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update

      Ended second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the approval of Aerpio shareholders and other customary closing conditions CINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update. Key Business Update: On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., a Delaware company ("Aadi"), and Aspen Merger Subsidiary, Inc., a D

      8/11/21 4:10:00 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting

      CINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing that a poster has been presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreement and Plan of Merger among Aerpio, Aadi, and Aspen Merger Subsidiary, Inc. About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on develo

      6/4/21 9:15:00 AM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting

      CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) announced that Aadi Bioscience ("Aadi"), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing its abstract to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. As previously disclosed, on May 16, 2021, Aerpio entered into an Agreement and Plan of Merger among Aerpio, Aadi, and Aspen Merger Subsidiary, Inc. About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compound

      5/19/21 7:52:31 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial

      CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company’s clinical assets and cash resources, which amounted to $47.3 million as of September 30, 2020. As part of this process, the Company will explore strategic options for partnering its programs, as well as, the potential for an acquisition, company sale, merger, business combination, asset sale, in-license, out-licens

      1/5/21 4:01:00 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Delaney Brendan

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      9/22/21 4:13:20 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by new insider Delaney Brendan

      3 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      9/22/21 4:07:42 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Desai Neil

      4 - Aadi Bioscience, Inc. (0001422142) (Issuer)

      9/10/21 5:05:21 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care

    $ARPO
    SEC Filings

    See more
    • SEC Form EFFECT filed by Aerpio Pharmaceuticals, Inc.

      EFFECT - Aadi Bioscience, Inc. (0001422142) (Filer)

      10/4/21 12:15:39 AM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 filed by Aerpio Pharmaceuticals, Inc.

      S-8 - Aadi Bioscience, Inc. (0001422142) (Filer)

      9/24/21 4:58:29 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care
    • SEC Form S-3 filed by Aerpio Pharmaceuticals, Inc.

      S-3 - Aadi Bioscience, Inc. (0001422142) (Filer)

      9/24/21 4:53:34 PM ET
      $ARPO
      Major Pharmaceuticals
      Health Care